Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03443089
Other study ID # GDN 022/16
Secondary ID
Status Completed
Phase Phase 1
First received February 16, 2018
Last updated February 22, 2018
Start date March 31, 2017
Est. completion date August 1, 2017

Study information

Verified date February 2018
Source Galeno Desenvolvimento de Pesquisas Clínicas
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial evaluated the comparative bioavailability of two injectable suspension formulations of medroxyprogesterone acetate + estradiol cypionate, a test (Depomês®, 25 mg/mL medroxyprogesterone acetate + 5 mg/mL estradiol cypionate, Biolab Sanus Farmacêutica Ltda.) and a reference formulation (Cyclofemina®, 25 mg/0.5 mL medroxyprogesterone acetate + 5 mg/0.5 mL estradiol cypionate, Millet Roux Ltda.) in healthy female volunteers after a single intramuscular dose administration. In addition, this study also evaluated the safety and tolerability of these drugs.


Description:

This study was performed in a monocentric, open label, parallel design, with 2 treatments, 1 period, in which twelve subjects received the test product (Depomês®, 25 mg/mL medroxyprogesterone acetate + 5 mg/mL estradiol cypionate, Biolab Sanus Farmacêutica Ltda.) and twelve subjects received the reference product (Cyclofemina®, 25 mg/0.5 mL medroxyprogesterone acetate + 5 mg/0.5 mL estradiol cypionate, Millet Roux Ltda.). The formulations (test or reference) were administered in a single intramuscular dose (1 ampoule) after an overnight fast (approximately 8 h). Blood samples (9 mL) were collected via a venous catheter into heparinized tubes at times pre-dose (0 h) and 6, 12, 24, 48, 72, 96, 120, 168, 240, 288, 336, 432, 504, 672, 840, 1008, 1176, 1344, 1512, 1680, 1848, and 2016 h after drug administration to measure medroxyprogesterone; and pre-dose (-48, -24 and 0 h) e 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, 240, 288, 336, 432, 504, 672, 840, and 1008 h after drug administration to measure estradiol cypionate.

The safety assessment was based on recording adverse events throughout the study duration. The subjects systolic and diastolic pressures, heart rate and temperature were determined prior and at approximately 4, 8 and 12 h after drug administration. The clinical evaluation and the laboratory tests were also performed at the end of the study.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date August 1, 2017
Est. primary completion date April 2, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Body-mass index (BMI) =19.0 kg/m² and = 27.5 kg/m²

- With regular cycles, without use of hormonal contraceptives (pills at least 3 months and injectables at least 1 year) and not using hormone replacement therapy

- Not pregnant or breastfeeding

- Good state of health

- Non-smoker or ex-smoker for at least 6 month

- Written informed consent, after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the subjects participating in the clinical trial

Exclusion Criteria:

- Existing cardiac, hepatic and/or haematological diseases or pathological findings, which might interfere with the safety or tolerability and/or pharmacokinetics and/or pharmacodynamics of the active ingredient

- History of relevant central nervous system (CNS) and/or psychiatric disorders and/or currently treated CNS and/or psychiatric disorders

- Known allergic reactions to the active ingredients used or to constituents of the pharmaceutical preparations

- Subjects with severe allergies or multiple drug allergies, unless it is judged as not relevant for the clinical trial by the investigator

- Positive anti-HIV-test (if positive to be verified by western blot), HBs-AGtest (if positive to be verified by test for HBc-IgM) or anti-HCV-test

- Admitted for any reason up to 8 weeks before the start of the first treatment period of this study

- History of or current drug or alcohol dependence

- Subjects who are on a diet which could affect the pharmacokinetics of the active ingredient

- Regular intake of caffeine containing food or beverages of = 500 mg caffeine per day

- Blood donation or other blood loss of more than 400 ml within the last 3 months prior to individual enrolment of the subject

- Participation in a clinical trial during the last 6 months prior to individual enrolment of the subject

- Positive pregnancy test, delivery or abortion in the 12 weeks prior to the planned hospitalization date.

- Subjects who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to during their participation in the clinical trial

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Test formulation
Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/mL + estradiol cypionate 5 mg/mL after an overnight fast.
Reference formulation
Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole after an overnight fast.

Locations

Country Name City State
Brazil Galeno Desenvolvimento de Pesquisas Clinicas Ltda. - ME Campinas SP

Sponsors (2)

Lead Sponsor Collaborator
Galeno Desenvolvimento de Pesquisas Clínicas Biolab Sanus Farmaceutica

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of medroxyprogesterone acetate and estradiol cypionate plasma levels Blood sampling for the determination of plasma levels of medroxyprogesterone acetate and estradiol cypionate in participants of each treatment group. 0-1008 hours after drug administration
Primary Measurement of estradiol cypionate plasma levels Blood sampling for the determination of plasma levels of estradiol cypionate in participants of each treatment group. -48 to 1008 hours after drug administration
Secondary Maximum Plasma Concentration (Cmax) of medroxyprogesterone acetate Determination of maximum plasma concentration of medroxyprogesterone acetate on plasma concentrations of samples obtained. 0 - 1008 hours after drug administration
Secondary Maximum Plasma Concentration (Cmax) of estradiol cypionate Determination of maximum plasma concentration of estradiol cypionate on plasma concentrations of samples obtained. 0 - 1008 hours after drug administration
Secondary Area Under the Curve (AUC) of medroxyprogesterone acetate Determination of area Under the Curve of medroxyprogesterone acetate from plasma concentrations versus time curve of samples obtained. 0 - 1008 hours after drug administration
Secondary Area Under the Curve (AUC) of estradiol cypionate Determination of area Under the Curve of estradiol cypionate from plasma concentrations versus time curves of samples obtained. 0 - 1008 hours after drug administration
Secondary Number of adverse events per participant Number of adverse events, in each treatment group, including clinically relevant alterations of vital signs and laboratory tests results. Up to 1008 hours after drug administration
See also
  Status Clinical Trial Phase
Completed NCT02577601 - Impact of Combined Hormonal Contraceptives on UPA Phase 4
Completed NCT03153644 - Improving Contraceptive Care for Women With Medical Conditions
Completed NCT04112095 - Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use Phase 3
Recruiting NCT05521646 - Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative N/A
Active, not recruiting NCT04291001 - Ovarian Function With ENG Implant and UPA Use Early Phase 1
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Completed NCT03438682 - Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
Active, not recruiting NCT01948882 - Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women N/A
Enrolling by invitation NCT04997499 - Adolescent Subcutaneous (SQ) Injection Video Validation N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03154125 - Sayana® Press Extension Study Phase 3
Withdrawn NCT03725358 - A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon. N/A
Completed NCT02957630 - "E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study" Phase 1/Phase 2
Completed NCT02718222 - Impact and Performance of Institutionalizing Immediate Post-partum IUD Services N/A
Completed NCT02456584 - Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods Phase 1
Recruiting NCT02121067 - LNG-IUS at 2 Weeks Postpartum Phase 4
Terminated NCT02169869 - Immediate Postplacental IUD Insertion N/A
Recruiting NCT02292056 - Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions N/A
Withdrawn NCT01930994 - Kenya Sino-implant (II) PK Study N/A